| Dr Harry Allen Roach, MD | |
|
4228 Houma Blvd Ste 130, Metairie, LA 70006-3003 | |
| (504) 454-2222 | |
| (504) 454-2388 |
| Full Name | Dr Harry Allen Roach |
|---|---|
| Gender | Male |
| Speciality | Thoracic Surgery |
| Experience | 44 Years |
| Location | 4228 Houma Blvd Ste 130, Metairie, Louisiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1396745089 | NPI | - | NPPES |
| 1370177 | Medicaid | LA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208G00000X | Thoracic Surgery (cardiothoracic Vascular Surgery) | 015840 (Louisiana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Family Homecare, Inc. | Metairie, LA | Home health agency |
| Tulane Medical Center | New orleans, LA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| East Jefferson Physicians Group Llc | 4587660402 | 177 |
News Archive
ZIOPHARM Oncology, Inc. announced today that the United States Food & Drug Administration (FDA) has granted Orphan Drug Designation to darinaparsin (Zinapar™ or ZIO-101) for the treatment of peripheral T-cell Lymphoma (PTCL). The United States Orphan Drug Act of 1983 was created to provide incentives for companies to develop and market treatments for diseases or conditions affecting fewer than 200,000 people in the United States.
NMS Labs launches another unique test suitable for the evaluation of toxicity vs. efficacy and helping physicians with therapeutic drug monitoring of patients for the therapeutic agent, Methotrexate.
INSYS Therapeutics, Inc. announces positive results from the pivotal phase III efficacy trial for patients utilizing the Fentanyl Sublingual Spray technology to treat breakthrough cancer pain. All primary and secondary endpoints were achieved in the study, and the drug is the first product to ever show statistically significant pain relief when measuring the summary of pain intensity difference at five minutes in a phase III breakthrough cancer pain trial using Fentanyl.
High blood pressure during pregnancy could dramatically raise a woman's lifetime risk of stroke, according to a study presented today at the Canadian Stroke Congress.
› Verified 8 days ago
| Entity Name | East Jefferson Physicians Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922293372 PECOS PAC ID: 4587660402 Enrollment ID: O20090127000299 |
News Archive
ZIOPHARM Oncology, Inc. announced today that the United States Food & Drug Administration (FDA) has granted Orphan Drug Designation to darinaparsin (Zinapar™ or ZIO-101) for the treatment of peripheral T-cell Lymphoma (PTCL). The United States Orphan Drug Act of 1983 was created to provide incentives for companies to develop and market treatments for diseases or conditions affecting fewer than 200,000 people in the United States.
NMS Labs launches another unique test suitable for the evaluation of toxicity vs. efficacy and helping physicians with therapeutic drug monitoring of patients for the therapeutic agent, Methotrexate.
INSYS Therapeutics, Inc. announces positive results from the pivotal phase III efficacy trial for patients utilizing the Fentanyl Sublingual Spray technology to treat breakthrough cancer pain. All primary and secondary endpoints were achieved in the study, and the drug is the first product to ever show statistically significant pain relief when measuring the summary of pain intensity difference at five minutes in a phase III breakthrough cancer pain trial using Fentanyl.
High blood pressure during pregnancy could dramatically raise a woman's lifetime risk of stroke, according to a study presented today at the Canadian Stroke Congress.
› Verified 8 days ago
| Entity Name | Metairie Physician Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801233648 PECOS PAC ID: 0749424802 Enrollment ID: O20130912000045 |
News Archive
ZIOPHARM Oncology, Inc. announced today that the United States Food & Drug Administration (FDA) has granted Orphan Drug Designation to darinaparsin (Zinapar™ or ZIO-101) for the treatment of peripheral T-cell Lymphoma (PTCL). The United States Orphan Drug Act of 1983 was created to provide incentives for companies to develop and market treatments for diseases or conditions affecting fewer than 200,000 people in the United States.
NMS Labs launches another unique test suitable for the evaluation of toxicity vs. efficacy and helping physicians with therapeutic drug monitoring of patients for the therapeutic agent, Methotrexate.
INSYS Therapeutics, Inc. announces positive results from the pivotal phase III efficacy trial for patients utilizing the Fentanyl Sublingual Spray technology to treat breakthrough cancer pain. All primary and secondary endpoints were achieved in the study, and the drug is the first product to ever show statistically significant pain relief when measuring the summary of pain intensity difference at five minutes in a phase III breakthrough cancer pain trial using Fentanyl.
High blood pressure during pregnancy could dramatically raise a woman's lifetime risk of stroke, according to a study presented today at the Canadian Stroke Congress.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Harry Allen Roach, MD 4228 Houma Blvd Ste 130, Metairie, LA 70006-3003 Ph: (504) 454-2222 | Dr Harry Allen Roach, MD 4228 Houma Blvd Ste 130, Metairie, LA 70006-3003 Ph: (504) 454-2222 |
News Archive
ZIOPHARM Oncology, Inc. announced today that the United States Food & Drug Administration (FDA) has granted Orphan Drug Designation to darinaparsin (Zinapar™ or ZIO-101) for the treatment of peripheral T-cell Lymphoma (PTCL). The United States Orphan Drug Act of 1983 was created to provide incentives for companies to develop and market treatments for diseases or conditions affecting fewer than 200,000 people in the United States.
NMS Labs launches another unique test suitable for the evaluation of toxicity vs. efficacy and helping physicians with therapeutic drug monitoring of patients for the therapeutic agent, Methotrexate.
INSYS Therapeutics, Inc. announces positive results from the pivotal phase III efficacy trial for patients utilizing the Fentanyl Sublingual Spray technology to treat breakthrough cancer pain. All primary and secondary endpoints were achieved in the study, and the drug is the first product to ever show statistically significant pain relief when measuring the summary of pain intensity difference at five minutes in a phase III breakthrough cancer pain trial using Fentanyl.
High blood pressure during pregnancy could dramatically raise a woman's lifetime risk of stroke, according to a study presented today at the Canadian Stroke Congress.
› Verified 8 days ago
Dr. James Mansel Tubb, M.D. Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Not Enrolled in Medicare Practice Location: 4228 Houma Blvd, Suite 300, Metairie, LA 70006 Phone: 504-454-2222 Fax: 504-454-2388 | |
Richard Gitter, MD Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Accepting Medicare Assignments Practice Location: 1 Galleria Blvd, Suite 100, Metairie, LA 70001 Phone: 504-833-0111 Fax: 504-833-0114 | |
Dr. Tod Clement Engelhardt, M.D. Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Accepting Medicare Assignments Practice Location: 4228 Houma Blvd Ste 130, Metairie, LA 70006 Phone: 504-454-2222 Fax: 504-454-2388 | |
Dr. Rudolph F Weichert Iii, MD Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Not Enrolled in Medicare Practice Location: 501 Rue Saint Peter, Unit 111, Metairie, LA 70005 Phone: 504-833-1304 Fax: 504-834-1306 | |
Dr. Michael Nelson Brothers, M.D. Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Accepting Medicare Assignments Practice Location: 4228 Houma Blvd Ste 130, Metairie, LA 70006 Phone: 504-454-2222 Fax: 504-454-2388 |